<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373036">
  <stage>Registered</stage>
  <submitdate>1/06/2017</submitdate>
  <approvaldate>31/07/2017</approvaldate>
  <actrnumber>ACTRN12617001120369</actrnumber>
  <trial_identification>
    <studytitle>Effects of Single dose Dexmedetomidine on recovery profile in ambulatory surgery</studytitle>
    <scientifictitle>Effect of single-dose dexmedetomidine on postoperative recovery after ambulatory ureteroscopy and ureteric stenting: a double blind randomized controlled study</scientifictitle>
    <utrn>U1111-1197-3249</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>post operative pain
</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sixty patients were randomised to receive IV dexmedetomidine 0.5 mcg.kg-1 (Group DEX, n=30) or IV 0.9% saline (Group P, n=30) as intravenous infusion  over 20 minutes at pre induction of anaesthesia  . </interventions>
    <comparator>The control group received intra venous saline 20 mls.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the effect of Dexmedetomidine on the patient's minimum alveolar concentration (MAC). The MAC of the patient is monitored using a tool already incorporated in the general anaesthesia machine.</outcome>
      <timepoint>every 5 minutes intraoperatively</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess postoperative pain scores using a pain assessment scale ie the visual analogue score which is widely used in many hospital around the world.</outcome>
      <timepoint>From immediately  post operation and every 12 hours for  3 days post operative.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients of American Society Anaesthesiologists physical status I-II, aged between 18-65 years who underwent elective ureteroscopy and ureteric stenting in our ambulatory day care centre. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>All patients with increased serum creatinine (&gt; 200ÂµmolL-1), advanced liver disease (liver enzymes twice the normal range or higher), those with a history of chronic use of sedatives/ narcotics or analgesics, known alcohol or drug abuse, allergy to study medication and those devoid of postoperative telephone access. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes that concealed group allocation. </concealment>
    <sequence>using a computer generated random number table in blocks of ten. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The sample size was based on our primary outcome measure of anaesthetic minimum alveolar concentration (MAC). From an initial pilot study involving 16 patients, we found the mean (SD) MAC of Sevoflurane to be 0.85 (0.19). We deemed a MAC reduction of 0.25 to be a clinically significant difference between the two groups. Prospective power analysis indicated that with a = 0.05 and power of 80%, 25 patients per group were needed. Therefore we recruited 30 patients per group to account for dropouts. Parametric data and non-parametric data was analysed with Students t test and Mann-Whitney U-test respectively, and Fishers exact test was used to compare side effects using SPSS 15.0 TM (SPSS Inc., Chicago, IL, USA) software. A p value of &lt; 0.05 was deemed statistically significant.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>21/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/04/2010</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>2/05/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University Malaya</primarysponsorname>
    <primarysponsoraddress>Dept of Anaesthesiology,
Faculty of Medicine,
Jalan Lembah Pantai,
50603 Kulala Lumpur,
Malaysia</primarysponsoraddress>
    <primarysponsorcountry>Malaysia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>university Malaya</fundingname>
      <fundingaddress>Dept of Anaesthesiology,
Faculty of Medicine,
Jalan Lembah Pantai,
50603 Kulala Lumpur,
Malaysia</fundingaddress>
      <fundingcountry>Malaysia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We evaluated the effect of a single pre-induction dose of dexmedetomidine on anaesthetic requirements, postoperative pain and clinical recovery after ambulatory ureteroscopy and ureteric stenting under general anaesthesia. Sixty patients were randomised to receive IV dexmedetomidine 0.5 mcg.kg-1 (Group DEX, n=30) or IV saline (Group P, n=30) maintained with Sevoflurane: oxygen: air, titrated to BIS 40-60. Pain intensity, sedation, rescue analgesics, nausea/vomiting and resumption of daily activities were recorded at 1 hour, and postoperative day (POD) 1-5. Group DEX patients had significant reduction in sevoflurane minimum alveolar concentration (MAC), mean (SD) DEX vs. Placebo 0.6 (0.2) vs. 0.9 (0.1), p = 0.037; reduced postoperative resting pain at 1hr (VAS 0-10) (mean (SD) 1.00 (1.84) vs. 2.63 (2.78), p = 0.004), POD 1 (mean (SD) 1.50 (1.48) vs. 2.87 (2.72), p = 0.002), POD 2 (0.53 (0.97) vs. 1.73 (1.96), p = 0.001) and POD 3 (0.30 (0.75) vs. 0.89 (1.49), p = 0.001). DEX patients also had less pain on movement POD 1 (3.00 (2.12) vs. 4.30 (3.10), p = 0.043) and POD 2 (2.10 (1.98) vs. 3.10 (2.46), p = 0.040), with higher resumption of daily activities by 48 hours compared to placebo, 87% vs. 63%, p = 0.04. We conclude that a single dose of dexmedetomidine was a useful adjuvant in reducing MAC and postoperative pain (at 1hr and POD 1-3), facilitating faster return to daily activities by 48hr.  </summary>
    <trialwebsite />
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Universiti Malaya Medical centre Ethics committee</ethicname>
      <ethicaddress>Jln Lembah Pantai,
50603 Kuala Lumpur</ethicaddress>
      <ethicapprovaldate>27/08/2008</ethicapprovaldate>
      <hrec>672.7</hrec>
      <ethicsubmitdate>30/07/2008</ethicsubmitdate>
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Ina Ismiarti Shariffuddin</name>
      <address>Dept of Anaesthesiology,
Faculty of Medicine,
Jln Lembah Pantai,
50603 Kuala Lumpur,
Malaysia</address>
      <phone>+60379492052</phone>
      <fax>+60379556705</fax>
      <email>inashariffuddin@gmail.com</email>
      <country>Malaysia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ina Ismiarti Shariffuddin</name>
      <address>Dept of Anaesthesiology,
Faculty of Medicine,
Jln Lembah Pantai,
50603 Kuala Lumpur,
Malaysia</address>
      <phone>+60379492052</phone>
      <fax>+60379556705</fax>
      <email>inashariffuddin@gmail.com</email>
      <country>Malaysia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ina Ismiarti Shariffuddin</name>
      <address>Dept of Anaesthesiology,
Faculty of Medicine,
Jln Lembah Pantai,
50603 Kuala Lumpur,
Malaysia</address>
      <phone>+60379492052</phone>
      <fax>+60379556705</fax>
      <email>inashariffuddin@gmail.com</email>
      <country>Malaysia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Ina Ismiarti Shariffuddin</name>
      <address>Dept of Anaesthesiology,
Faculty of Medicine,
Jln Lembah Pantai,
50603 Kuala Lumpur,
Malaysia</address>
      <phone>+60379492052</phone>
      <fax>+60379556705</fax>
      <email>inashariffuddin@gmail.com</email>
      <country>Malaysia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>